AU4206489A - Recombinant vaccinia virus for prevention of disease caused by flavivirus - Google Patents
Recombinant vaccinia virus for prevention of disease caused by flavivirusInfo
- Publication number
- AU4206489A AU4206489A AU42064/89A AU4206489A AU4206489A AU 4206489 A AU4206489 A AU 4206489A AU 42064/89 A AU42064/89 A AU 42064/89A AU 4206489 A AU4206489 A AU 4206489A AU 4206489 A AU4206489 A AU 4206489A
- Authority
- AU
- Australia
- Prior art keywords
- virus
- dengue
- recombinant
- flavivirus
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700618 Vaccinia virus Species 0.000 title claims description 25
- 241000710831 Flavivirus Species 0.000 title claims description 19
- 230000006806 disease prevention Effects 0.000 title description 2
- 208000025729 dengue disease Diseases 0.000 claims description 38
- 206010012310 Dengue fever Diseases 0.000 claims description 36
- 208000001490 Dengue Diseases 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000001681 protective effect Effects 0.000 claims description 9
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 38
- 101710128560 Initiator protein NS1 Proteins 0.000 description 38
- 101710144127 Non-structural protein 1 Proteins 0.000 description 38
- 241000725619 Dengue virus Species 0.000 description 25
- 206010046865 Vaccinia virus infection Diseases 0.000 description 23
- 208000007089 vaccinia Diseases 0.000 description 23
- 108090000288 Glycoproteins Proteins 0.000 description 22
- 102000003886 Glycoproteins Human genes 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 101710172711 Structural protein Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 7
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
- 241000725643 Respiratory syncytial virus Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101800000512 Non-structural protein 1 Proteins 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710195254 Non-structural glycoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940012229 genone Drugs 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
RECOMBINANT VACCINIA VIRUS FOR PREVENTION
OF DISEASE CAUSED BY FLAVIVIRUS
Technical Field
The present invention is related to the construction of recombinant vaccinia viruses. More particularly, the present invention is related to the construction of recombinant vaccinia viruses which are useful for the preparation of a vaccine for the prevention of diseases caused by flaviviruses, such as dengue virus, Japanese B encephalitis virus and tick-borne encephalitis virus.
Background of the Invention
Certain diseases of public health concern, such as dengue disease and encephalitis of certain types are known to be caused by viruses belonging to the flavivirus family. It has been estimated that up to 100 million illnesses occur every year in tropical areas of the world due to dengue virus alone. However, there is no effective and specific immunoprophylactic measure to control such flavivirus diseases.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a recombinant vaccinia virus which induces an immune response against a specific flavivirus disease in a host infected with said recombinant vaccinia virus.
Other objects and advantages of the present invention will become evident from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein:
Figure 1 shows schematic construction of a dengue virus-vaccinia virus recombinant plasmid. The intermediate cloning vector pscll contains interrupted
thymidine kinase gene sequences (TKR amd TKL) and a bacterial β-galactosidase gene (LacZ) under the transcription control of the P11 vaccinia virus promoter. The vector DNA was partially digested with BamHI to open the BamHI site downstream of the P7.5 promoter for insertion of the 4.1 kilobase (Kb} fragment of dengue virus DNA located at the 5' end of the viral genone. This fragment of dengue cDNA contains the coding region for the three dengue structural proteins [capsid (C), pre-membrane (pre-M), and envelope glycoprotein (E)] plus the first two downstream non-structural proteins NS1 and NS2a. Recombinant plasmid containing the dengue virus DNA insert in the sense transcription orientation was selected and used for construction of the recombinant vaccinia virus.
Figures 2A and 2B demonstrate the identification of dengue virus proteins synthesized by the recombinant vaccinia virus. (Figure 2A: ) Immunoprecipitation of [35S]-methionine-labeled lysate from recombinant vaccinia virus-infected cells (multiplicity of infection, 10 PFU per cell) was carried out with one of the following specific antibodies, monoclonal antibody 1H10, specific for the envelope glycoprotein (E); rabbit antibodies prepared against dengue virus type 2 nonstructural protein l(NSι); monoclonal antibody 5C9 specific for the membrane glycoprotein precursor (preM); and polyvalent antibodies (P). The labeled precipitates were analyzed on sodium dodecyl sulfate-12% polyacrylamide gels. Also shown are the labeled dengue virus protein markers (D) obtained by immunoprecipitation with polyvalent antibodies of [35S]-methionine-labeled lysate from dengue virus-infected CV-1 cells. (Figure 2B: ) Labeled immunoprecipitates prepared as described above were analyzed by digestion with endoglycosidase H (endo H) and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Numbers at the left of the gels indicate protein sizes in kilodaltons.
DETAILED DESCRIPTION OF THE INVENTION
The above and various other objects and advantages of the present invention are achieved by a recombinant vaccinia virus containing complete coding sequence for the expression of the major specific protective flavivirus antigens in cells infected with said recombinant vaccinia virus, said antigens inducing protective immunity against infection by said flavivirus in a susceptible host.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. Unless mentioned otherwise, the techniques employed herein are standard methodologies well known to one of ordinary skill in the art.
Like other members of the flavivirus family, extracellular dengue virus has a relatively simple structure. Virions contain only three virus-coded proteins, designated capsid (C) protein, membrane (M) protein, and envelope (E) glycoprotein. Intracellular virus, which is also infectious, lacks M but contains another glycoprotein, preM, from which M is derived by cleavage. Both C and M are internal proteins. The surface envelope glycoprotein is the major site responsible for neutralization of infectivity by specific antibodies. The envelope glycoprotein also exhibits hemagglutinating activity and is responsible for adsorption to the cell surface. Several nonstructural proteins have also been identified in dengue virus-infected cells. Among them is nonstructural protein NS1, which is a glycoprotein and described as a soluble complement-fixing
antigen. It is believed that NS1 plays an important role in mediating immunity, since the analogous NS1 glycoprotein of yellow fever virus has been shown to be a protective antigen in mice and in primates. Furthermore, the NS1 of dengue type 2 virus has been shown to be a protective antigen.
The dengue type 4 virus genome consists of a molecule of positive-stranded RNA 10,644 nucleotides in length. A full-length cDNA copy of the dengue type 4 virus has been prepared, and its complete nucleotide sequence determined. From such studies, it has been estimated that 96% of the dengue virus genome codes for a polyprotein which is cleaved by specific protease(s) to generate individual viral proteins. The three structural proteins, C-M-E, are located at the amino terminus, while nonstructural proteins NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5 are at the carboxy-terminus. It must be emphasized that because dengue virus gene expression involves proteolytic cleavage of the polyprotein, it cannot be assumed a priori that the expression of protective antigens such as E and NS1 from their cloned DNA sequences, would be useful in immunoprophylaxis. Such determination can be made only through actual testing. The construction of a vaccinia flavivirus recombinant is now illustrated by employing dengue virus genes as an example .
Vaccinia virus was used as a vector for construction of a live recombinant virus expressing dengue viral genes. The BglII DNA fragment (4,041 base pairs, nucleotides 88 to 4128) from the 5' terminus of dengue type 4 virus cDNA contains the coding region for the three structural proteins as well as nonstructural proteins NS1 and NS2a. This fragment was excised from the full-length dengue virus DNA copy and was inserted into the PSC11 vaccinia intermediate vector. The dengue virus DNA sequence was inserted in the BamHI site immediately downstream of the vaccinia P7.5 early-late promoter (Figure 1). In this construct, the dengue virus coding
sequence was placed under the transcriptional control of the vaccinia virus P7.5 early-late promoter. The vector contained a bacterial -galactosidase gene under the control of the vaccinia virus P11 late promoter, which provided a visual selectable marker. The chimeric genes were flanked by sequences of the vaccinia virus thymidine kinase gene, which directed homologous recombination of dengue virus sequences into the vaccinia virus genome following transfection of simian CV-1 cells previously infected with wild type vaccinia virus (WR strain). Recombinant vaccinia virus harboring the dengue virus DNA insert was isolated and plaque purified two times on thymidine kinase minus (TK) cells in selective medium. Other dengue cDNA fragments, vide infra, were inserted into a vaccinia recombinant virus by the method just described. Similarly, constructs of other flavivirusvaccinia recombinants are made by inserting flavivirus cDNA following the procedure described herein for dengue virus.
Dengue virus-specific proteins synthesized during infection with the recombinant virus were initially detected by indirect immunofluorescence. CV-1 cells infected with the recombinant virus exhibited fluorescent-stainable antigens in the cytoplasm when polyvalent dengue type 4 virus hyperimmune mouse antiserum was used, although the intensity of staining was less than that observed in dengue virus-infected cells. Similar immunofluorescence was observed in CV-1 cells infected with the recombinant virus when monoclonal antibody specific to the E glycoprotein was used.
To further identify this and other dengue virus proteins, recombinant virus-infected cells were radiolabeled with [35]methionine and the cell lysate was prepared for immunoprecipitation by specific antibodies. Analysis of the labeled precipitate on sodium dodecyl sulfate-polyacrylamide gel (Figure 2A) showed that the polyvalent hyperimmune mouse antiserum precipitated three
major bands with estimated molecular size 20, 40 to 46, and 55 to 60 kilodaltons (kDa), respectively. Minor bands of larger molecular size that were probably nonspecific were also observed. When an E glycoproteinspecific monoclonal antibody (1H10) was used, a 55 to 60kDa band consistent with the molecular size of the E glycoprotein was precipitated. Similarly, dengue type 2 virus NS1-specific antiserum (obtained from Dr. J. Schlesinger) precipitated a 40- to 46-kDa band, which is the predicted size for the NS1 nonstructural glycoprotein. The third major band precipitated by dengue type 4 virus hyperimmune antiserum was approximately 20 kDa which is consistent with the size of the intracellular preM glycoprotein. A similar band was precipitated by preM-specific antibodies (monoclonal antibody 2H2 or 5C9, obtained from Dr. M. K. Gentry of WRAIR).
Thus, in recombinant virus-infected cells, the three glycoproteins encoded in the cloned DNA appeared to be cleaved and modified by glycosylation in a manner similar to that observed during dengue virus infection. This suggests that the dengue viral structural proteins, as well as the NS1 nonstructural protein, were specifically processed by proteolytic cleavage of the polyprotein in the absence of dengue virus functions provided by the distal nonstructural proteins NS2b through NS5. However, as estimated by immunoprecipitation, the amount of dengue preM, E nad NS1 glycoproteins produced in recombinant virus infected cells was significantly less than in dengue type 4 virus-infected cells.
The pattern of glycosylation of the glycoproteins produced in recombinant virus-infected cells varied as indicated by their response to endoglycosidase H, which cleaves the mannose rich carbohydrate core. The preM protein band was completely sensitive to endoglycosidase H treatment, yielding a band of 17 kDa, a reduction of 3 kDA in molecular size. On the other hand, a significant portion of the carbohydrate of both the E
and the NS1 glycoproteins appeared to be resistant to endoglycosidase H digestion.
Each of the dengue virus glycoproteins, i.e., preM, E and NS1, is preceded by a stretch of hydrophobic amino acids which can serve as a signal. This indicates that cellular signalase is probably responsible for proteolytic cleavage. Presumably, the cleavage mechanism which generates the three glycoproteins, also yields the capsid protein, which is located amino terminal to the preM glycoprotein.
As described herein above, initially a recombinant vaccinia virus containing a 4.0 Kb sequence from the 5' terminus of cDNA that codes for the three structural proteins [capsid (C), membrane (M), and envelope (E)] and nonstructural proteins NS1 and NS2a was constructed. Subsequently, another recombinant vaccinia virus expressing only the three structural proteins was constructed by deleting the coding sequence for nonstructural proteins. Protein analysis showed that cells infected with the first recombinant virus v(C-M-E-NS1NS2a) produced authentic pre-membrane (preM), envelope (E), and NS1 glycoproteins as detected by radioimmunoprecipitation using specific antibodies. These dengue proteins showed a glycosylation pattern similar to that found for these proteins produced during dengue virus infection. The second recombinant virus (C-M-E) produced dengue virus preM and E glycoproteins. As expected, NS1 was not synthesized by the second recombinant (Table 2).
The mouse model of dengue encephalitis was employed to evaluate protective immunity induced by these recombinants. Mice were inoculated by the intraperitoneal route with 107 plaque forming units (pfu) of recombinant vaccinia virus. Mice were reinoculated with the same dose of recombinant two weeks later. One week after the second inoculation themice were challenged with 100 LD50 of denque virus intracerebrally. The animals were then observed for signs of encephalitis and death.
Ninety-one percent of mice immunized with a control vaccinia recombinant virus expressing the envelope glycoprotein of HIV died after challenge (Tables 1 and 2). In contrast, 96% of mice immunized with the vaccinia (C-M-ENS1-NS2a) recombinant that expressed the three structural proteins and NS1, survived. Also, all 15 animals immunized with the vaccinia (C-M-E) recombinant virus that expressed only the three structural proteins were completely protected. These results indicate that structural proteins alone are able to induce protective immunity. Since C and M are internal proteins, it is concluded that E is the major antigen responsible for protection conferred by the v(C-M-E) recombinant. This interpretation is supported by the complete resistance to intracerebral challenge induced by immunization with faccinia recombinants that expressed only the E glycoprotein. Data in Table 1 provide such evidence. A recombinant that expressed E including its N-terminal hydrophobic signal sequence, or a respiratory syncytial virus (RSV) G glycoprotein (amino acids 1 through 70) - E fusion protein or an influenza A virus hemagglutinin N terminal signal peptide - E fusion protein induced complete protection against dengue virus challenge.
The seroresponse of animals immunized with these recombinants was tested by radioimmunoprecipitation of labeled antigens. Each of the animals immunized with the v(C-M-E-NS1-NS2a) recombinant that expressed the three structural proteins and NS1, developed NS1 antibodies, while the amount of antibody to E was low or not detectable. The low level of E antibody response was further confirmed by other serologic tests such as virus neutralization and ELISA. Also, mice infected with the vaccinia recombinant (C-M-E) that expressed only the three structural proteins developed little or no detectable E antibody.
The nonstructural protein NS1 expressed by various vaccinia recombinant viruses was also evaluated
for its antigenic properties and the most promising products were evaluated for their protective effect in mice. A total of 6 NS1 vaccinia recombinants were studied. These recombinants contained an insert in which: (i) NS1 was preceded by the structural protein sequence (C-M-E), (ii) NS1 was preceded only by its immediate upstream hydrophobic sequence or (iii) NS1 was not preceded by structural genes or its immediate upstream hydrophobic sequence. Each of these inserts terminated with the complete NS2a sequence or the N terminal 15% of the NS2a sequence. The v(C-M-E-NS1-NS2a) and v(NS1-NS2a) recombinants produced authentic NS1, whereas other recomtbinants that lacked the NS1 N terminal hydrophobic signal or lacked the complete downstream NS2a sequence yielded a NS1 product of different molecular size and/or were not glycosylated as indicated by gel analysis. From these studies it was concluded that the N-terminal signal sequence of NS1 and the complete downstream NS2a sequence are required for proper processing and proteolytic cleavage of NS1.
The above mentioned NS1 recombinants were then evaluated for their prophylactic potential in mouse protection studies as described above. The results indicated that all but one of 28 mice inoculated with vaccinia (C-M-E-NS1-NS2a) recombinant expressing the structural proteins and NS1 survived dengue challenge (Table 1). Significantly, the recombinant which expressed authentic NS1 in the absence of structural proteins, i.e., v(NS1-NS2a), induced complete resistance to lethal challenge with dengue virus (Table 2). Other vaccinia recombinants that expressed abnormal NS1 induced only partial protection. Thus, vaccination with a vaccinia recombinant that expressed (i) an upstream Nterminal RSV G sequence (amino acids 1-70) fused to NS1 or (ii) NS1 plus 15% of NS2a, induced only partial protection.
These tests demonstrate that dengue envelope
(E) glycoprotein and nonstructural protein NS1 are separate protective antigens, each of which can induce complete resistance to encephalitis in the mouse model of dengue disease. These results now allow the development of vaccinia recombinants expressing E and/or NS1 glycoprotein as vaccines for protection of humans against dengue type 4 virus. Accordingly, a vaccine comprises an immunogenic amount of the recombinant vaccinia virus which induces protective immunity against a specific flavivirus in a host infected with said recombinant vaccinia virus. Conventional pharmaceutically acceptable carrier or vehicles such as non-toxic buffers, physiological saline and the like could be used together with adjuvants and booster inoculations, if necessary. Of course, the vaccine can be administered in a single or multiple dosages as indicated.
It is important to point out here that a vaccinia-dengue type 2 virus recombinant that contained the dengue sequences for C,M, and E controlled by a P11 vaccinia virus promoter was recently reported by Deubel et al, 1988 (J. Gen. Virol. 69:1921-1929) and failed to protect monkeys against dengue. In contrast, the recombinant of the present invention was efficacious in protecting the test animals against viral infection.
Since the genome organization, replication strategy and gene expression of all flaviviruses are similar, recombinant vaccinia viruses having prophylactic property against other flaviviruses are made in a manner similar to the herein illustrated vaccinia-dengue construct.
A deposit of the recombinant virus has been made at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., on August 19, 1988 under the accession number VR 2228. The deposit shall be viably maintained, and replaced if it becomes non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of
request for a sample of the deposit, whichever is longer, and made available to the public without restriction in accordance with the provisions of the law. The Commissioner of Patents and Trademarks, upon request, shall have access to the deposit.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
TABLE 1
MICE INFECTED WITH VACCINIA RECOMBINANTS EXPRESSING
DENGUE ENVELOPE (E) GLYCOPROTEIN WITH OR WITHOUT NONSTRUTCTURAL NS1 GLYCOPROTEIN DEVELOP RESISTANCE TO FATAL CHALLENGE WITH DENGUE VIRUS
NO. WHICH SURVIVED
VACONIA RECOMEXPRESSION OF NO. OF AN INTRACEREBRAL
BINANT EXPRESSING MICE CHALLENGE WITH 102 DENGUE PROTEIN(S) GLYCOAUTHENINFECTED LD50 DENGUE TYPE
SYLATED E TIC NS1 (107 PFU) 4 VIRUS
v(C-M-E-NS1-NS2A) YES YES 28 27 ( 96%) v(C-M-E-NS1-NS2A Δ)* YES NO 15 15 (100%) v(C-M-E) YES - 19 19 (100%) v(E) YES - 15 15 (100%) v(RSV G-E)+ YES - 15 15 (100%) v(FLU HA-E)++ YES - 15 15 (100%) v(HIV GP160)+++ - - 46 4 (8.7%)
*
85% OF C TERMINAL SEQUENCE OF NS2A DELETED.
**
SURVIVING MICE DEVELOPED MILD SIGNS OF ENCEPΗALITIS.
+ EXPRESSES FUSION PROTEIN OF N TERMINUS OF RSV G (AMINO ACIDS 1¬
70) PLUS E.
++ EXPRESSES FUSION PROTEIN OF INFLUENZA A VIRUS N TERMINAL SIGNAL
PEPTIDE PLUS E.
+++ CONTROL VACCINIA RECOMBINANT EXPRESSING ENVELOPE GLYCOPROTEIN OF
HIV.
TABLE 2
MICE INFECTED WITH VACCINIA RECOMBINANT EXPRESSING ONLY
DENGUE NONSTRUCTURAL PROTEIN NS1 DEVELOP RESISTANCE
TO FATAL CHALLENGE WITH DENGUE VIRUS
NO. WHICH SURVIVED AN
VACCINIA RECOMEXPRESSION OF NO. OF MICE INTRACEREBRAL CHALBINANT EXPRESSING AUTHENTIC NS1 INFECTED LENGE WITH 102 LD50 INDICATED (107 PFU) DENGUE TYPE 4 VIRUS DENGUE PROTEIN(S)
v(NS1-NS2A) YES 15 15 (100%)
v(NS1-NS2A Δ)* NO 30 20 ( 67%)
v(RSV G-NS1)+ NO 15 8 ( 54%)
v(HTV GP16O)++ - 46 4 (8.7%)
* 85% OF C TERMINAL SEQUENCE OF NS2A DELETED.
+ EXPRESSES FUSION PROTEIN OF RSV G (AMINO ACIDS 1-70) PLUS NS1.++ CONTROL VACCINIA RECOMBINANT EXPRESSING ENVELOPE GLYCOPROTElN OF
HIV.
Claims (6)
1. A recombinant vaccinia virus containing complete coding sequence for the expression of flavivirus antigenic proteins.
2. The virus of claim 1 wherein said flavivirus is a dengue type 4 virus.
3. The virus of claim 1 wherein said flavivirus is a Japanese B or tick-borne encephalitis virus.
4. The virus of claim 1 wherein said antigenic protein is selected from the group consisting of a part or whole of an envelope glycoprotein, capsid protein, pre-matrix protein, NS1, NS2 nonstructural protein and a combination thereof.
5. A pharmaceutical composition, comprising an immunogenic amount of the virus of claim 1 in a pharmaceutically acceptable carrier.
6. A method for inducing protective immunity against a flavivirus disease, comprising inoculating a host susceptible to flavivirus with an immunogenic amount of the virus of claim 1 in a single or multiple dosages.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23920588A | 1988-08-20 | 1988-08-20 | |
| US239205 | 1988-08-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4206489A true AU4206489A (en) | 1990-03-23 |
| AU624863B2 AU624863B2 (en) | 1992-06-25 |
Family
ID=22901085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU42064/89A Ceased AU624863B2 (en) | 1988-08-20 | 1989-08-21 | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0431064A4 (en) |
| JP (1) | JPH03503364A (en) |
| AU (1) | AU624863B2 (en) |
| IL (1) | IL91304A0 (en) |
| WO (1) | WO1990001946A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU667836B2 (en) * | 1991-09-19 | 1996-04-18 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Chimeric and/or growth-restricted flaviviruses |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| HUT54306A (en) * | 1989-06-06 | 1991-02-28 | Immuno Ag | Process for producing proteins, vaccines and nucleic acids |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US6117640A (en) * | 1995-05-02 | 2000-09-12 | The United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine made in E. coli against dengue virus |
| ES2184869T3 (en) * | 1995-05-24 | 2003-04-16 | Hawaii Biotech Group | SUB-UNIT VACCINE AGAINST INFECTION WITH FLAVIVIRUS. |
| ID19548A (en) * | 1996-09-24 | 1998-07-23 | Bavarian Nordic Res Inst As | RECOMBINED MVA VIRUSES EXPRESSING FEATURES ANTIGENS AND FEVER USING THEMS IN VACCINES |
| PL192957B1 (en) * | 1997-02-28 | 2006-12-29 | Acambis Inc | Chimeric flaviviral vaccines |
| IL139844A0 (en) | 1998-06-04 | 2002-02-10 | Us Gov Health & Human Serv | Nucleic acid vaccines for prevention of flavivirus infection |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| EP2278012B1 (en) | 2000-02-16 | 2015-08-26 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Immunogenic Dengue 2 virus chimeras |
| WO2003048184A2 (en) * | 2001-12-04 | 2003-06-12 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| WO2014150939A2 (en) | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc | Compositions and methods for dengue virus chimeric constructs in vaccines |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| JP2021536463A (en) | 2018-09-05 | 2021-12-27 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | Dengue vaccine unit dose and its administration |
| EP3939607A4 (en) * | 2019-03-14 | 2023-01-25 | Tokyo Metropolitan Institute of Medical Science | Dengue virus vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH084508B2 (en) * | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | Recombinant vaccinia virus |
-
1989
- 1989-08-14 IL IL91304A patent/IL91304A0/en unknown
- 1989-08-21 WO PCT/US1989/003589 patent/WO1990001946A1/en not_active Application Discontinuation
- 1989-08-21 EP EP19890910317 patent/EP0431064A4/en not_active Withdrawn
- 1989-08-21 JP JP1509348A patent/JPH03503364A/en active Pending
- 1989-08-21 AU AU42064/89A patent/AU624863B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU667836B2 (en) * | 1991-09-19 | 1996-04-18 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Chimeric and/or growth-restricted flaviviruses |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990001946A1 (en) | 1990-03-08 |
| AU624863B2 (en) | 1992-06-25 |
| JPH03503364A (en) | 1991-08-01 |
| EP0431064A4 (en) | 1991-11-13 |
| IL91304A0 (en) | 1990-03-19 |
| EP0431064A1 (en) | 1991-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU624863B2 (en) | Recombinant vaccinia virus for prevention of disease caused by flavivirus | |
| Zhao et al. | Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus | |
| JP3531934B2 (en) | Chimeric and / or growth-restricted flavivirus | |
| JP4500049B2 (en) | Flavivirus NS1 subunit vaccine | |
| JP4504464B2 (en) | Chimeric flavivirus vaccine | |
| Falgout et al. | Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis | |
| Chen et al. | Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines | |
| US5494671A (en) | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins | |
| Bray et al. | Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence | |
| US8088391B2 (en) | West nile virus vaccine | |
| KR20010022452A (en) | Recombinant dimeric envelope vaccine against flaviviral infection | |
| Bonaldo et al. | Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus | |
| Jan et al. | Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein | |
| Chia et al. | Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge | |
| US6676936B1 (en) | Chimeric and/or growth-restricted flaviviruses | |
| ES2637629T3 (en) | Induction of an immune response against dengue virus using a sensitization-enhancement approach | |
| Hahn et al. | Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses | |
| WO1992003161A1 (en) | Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection | |
| Venugopal et al. | Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins | |
| AU674134B2 (en) | Recombinant viruses comprising artificial proteolytic cleavage site | |
| Kinney | The structural genes of Venezuelan equine encephalitis virus: molecular cloning, sequencing and expression in recombinant vaccinia virus | |
| WO1991002819A1 (en) | Recombinant japanese encephalitis molecules and methods of use therefor | |
| WGGA et al. | 465 JMENTATION PAGE] _ |